In a report released today, Serge Belanger from Needham maintained a Buy rating on Aerie Pharma (AERI – Research Report), with a price target of $22.00. The company's shares closed last Thursday at $7.11, close to its 52-week low of $6.67. According to TipRanks.com, Belanger is a 2-star analyst with an average return of 0.4% and a 38.4% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical. Currently, the analyst consensus on Aerie Pharma is a Strong Buy with an average price target of $18.00, which is a 153.2% upside from current levels.
https://www.tipranks.com/news/blurbs/needham-thinks-aerie-pharmas-stock-is-going-to-recover-6?utm_source=advfn.com&utm_medium=referral
Aerie Pharmaceuticals (NASDAQ:AERI)
Gráfico Histórico do Ativo
De Jul 2022 até Ago 2022 Click aqui para mais gráficos Aerie Pharmaceuticals.
Aerie Pharmaceuticals (NASDAQ:AERI)
Gráfico Histórico do Ativo
De Ago 2021 até Ago 2022 Click aqui para mais gráficos Aerie Pharmaceuticals.